Kaplan-Meier estimate (P) of a one-year failure-free survival of patients randomized to receive MTX as intravenous infusion either over 4 hours or over 24 hours. Intent-to-treat analysis. (A) For the whole group; (B) for patients in risk group R2; and (C) for patients in combined risk groups R3 + R4. SE indicates standard error.